Journal
CURRENT CANCER DRUG TARGETS
Volume 12, Issue 8, Pages 1032-1042Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156800912803251180
Keywords
CDC42; glioma; invasion; LRRC4; miRNA; RhoA
Categories
Funding
- National Science Foundation of China [81171932, 30901539]
- Program for New Century Excellent Talents in University [NCET-08-0562]
- Hunan Province Natural Sciences Foundations of China [11JJ1013]
- Research Fund for the Doctoral Program of Higher Education of China [20110162110037]
Ask authors/readers for more resources
Leucine-rich repeat (LRR) genes encode transmembrane proteins that are essential for normal brain development and are often dysregulated in central nervous system tumors. Leucine-rich repeat C4 (LRRC4) is a member of the LRR protein superfamily and specifically expressed in brain tissue. Importantly it acts as a tumor suppressor in the pathogenesis of malignant gliomas. However, the molecular mechanisms by which LRRC4 regulates glioma tumorigenesis are largely unknown. In this report, we found that miR-185 is markedly upregulated by LRRC4. We also found that miR-185 was downregulated in glioma, and overexpression of miR-185 inhibited glioma cell invasion. Low expressions of LRRC4 and miR-185 were associated with a poor outcome in glioma patients. Further investigation revealed that LRRC4 mediated its tumor suppressor function by regulating miR-185 targets CDC42 and RhoA. LRRC4 overexpression inhibited glioma cell invasion through miR-185-mediated CDC42 and RhoA direct regulation and VEGFA indirect regulation. Together, our findings suggest that the altered expression of the tumor suppressor LRRC4 may be an important event that leads to the dysregulation of miR-185 in human gliomas. LRRC4 and miR-185 may also be good prognostic markers and therapeutic targets in glioma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available